BeiGene (BGNE) Stock Price, News & Analysis

Company Overview

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Key Stats

• Today's Range: $232.77 to $237.95
• 50-Day Range: $156.98 to $233.60
• 52-Week Range: $126.97 to $238.80
• Volume: 216,637 shs
• Average Volume: 251,529 shs
• Market Capitalization: $22.92 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $241.21
• Consensus Rating: Moderate Buy

BeiGene Stock Analysis - MarketRank™

BeiGene scored higher than 24% of companies evaluated by MarketBeat, and ranked 871st out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BeiGene has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

BeiGene has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BeiGene are expected to grow in the coming year, from ($5.13) to ($0.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BeiGene is -31.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BeiGene is -31.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BeiGene has a P/B Ratio of 6.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.06% of the outstanding shares of BeiGene have been sold short.

Short Interest Ratio / Days to Cover

BeiGene has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in BeiGene has recently decreased by 11.11%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BeiGene does not currently pay a dividend.

Dividend Growth

BeiGene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.06% of the outstanding shares of BeiGene have been sold short.

Short Interest Ratio / Days to Cover

BeiGene has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in BeiGene has recently decreased by 11.11%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.50

News Sentiment

BeiGene has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for BeiGene this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for BGNE on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BeiGene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,601,007.00 in company stock.

Percentage Held by Insiders

Only 7.43% of the stock of BeiGene is held by insiders.

Percentage Held by Institutions

48.55% of the stock of BeiGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BGNE Stock Analysis - Frequently Asked Questions

How have BGNE shares performed this year?

BeiGene's stock was trading at $180.36 on January 1st, 2024. Since then, BGNE stock has increased by 30.2% and is now trading at $234.82.
View the best growth stocks for 2024 here.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) announced its earnings results on Wednesday, August, 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.27) by $1.12. The company's revenue was up 56.1% on a year-over-year basis.

When did BeiGene IPO?

BeiGene (BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

How do I buy shares of BeiGene?

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD) and Intel (INTC).

Company Calendar

• Last Earnings: 8/07/2024
• Today: 10/03/2024
• Next Earnings (Estimated): 11/14/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BGNE
• CUSIP: N/A
• CIK: 1651308
• Web: www.beigene.com
• Phone: (345) 949-4123
• Fax: N/A
• Employees: 10,600
• Year Founded: 2010

Price Target and Rating

• Average Stock Price Target: $241.21
• High Stock Price Target: $345.00
• Low Stock Price Target: $152.50
• Potential Upside/Downside: +3.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($7.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-881,710,000.00
• Net Margins: -16.91%
• Pretax Margin: -15.20%
• Return on Equity: -14.93%
• Return on Assets: -9.22%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 1.98
• Quick Ratio: 1.75

Sales & Book Value

• Annual Sales: $3.10 billion
• Price / Sales: 7.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $37.10 per share
• Price / Book: 6.30

Miscellaneous

• Outstanding Shares: 96,903,000
• Free Float: 89,703,000
• Market Cap: $22.64 billion
• Optionable: Optionable
• Beta: 0.61